title: [Effects of ligustrazine injection on high glucose-induced type I collagen, matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 expressions in human peritoneal mesothelial cells in vitro].
abstract: OBJECTIVE
  To investigate the effects of ligustrazine injection on type I collagen, matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of metalloproteinase-1 (TIMP-1) expressions in human peritoneal mesothelial cells (HPMCs) cultured in high glucose conditions.
  
  
  METHODS
  HPMCs were isolated from human omenta by trypsin digestion method and subcultured. Then, the HPMCs were divided into normal control group, high glucose group and high glucose plus low-, medium- and high-dose ligustrazine (10, 20 and 40 mg/L ligustrazine respectively) groups. Semi-quantitative reverse transcription-polymerase chain reaction was used to detect the expressions of type I collagen, MMP-1 and TIMP-1 mRNAs in HPMCs. Proteins of type I collagen, MMP-1 and TIMP-1 in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Cell protein concentration was measured by trace bicinchoninic acid method to correct the ELISA assay results.
  
  
  RESULTS
  Ligustrazine injection could significantly decrease high glucose-induced type I collagen and TIMP-1 expressions in a dose-dependent manner both in protein and gene levels (P<0.05, P<0.01). In addition, medium- and high-dose ligustrazine injection could significantly increase MMP-1 expression which was inhibited by high glucose concentrations (P<0.05).
  
  
  CONCLUSIONS
  Ligustrazine injection does not only decrease type I collagen synthesis, but also promote its degradation by modulating unbalanced MMP-1/TIMP-1 expression in HPMCs cultured in high glucose conditions.
authors.affiliation: Department of Nephrology, Nanjing University Medical School, Nanjing, China.
authors.forename: Gui-song
authors.initials: GS
authors.lastname: Zhu
authors.forename: Jin-song
authors.initials: JS
authors.lastname: He
mesh_terms: D002478:Cells, Cultured; D024042:Collagen Type I / Q000378:metabolism; D004847:Epithelial Cells / Q000187:drug effects* / Q000378:metabolism*; D005947:Glucose / Q000009:adverse effects; D006801:Humans; D020781:Matrix Metalloproteinase 1 / Q000378:metabolism*; D010529:Peritoneal Cavity / Q000166:cytology; D011719:Pyrazines / Q000494:pharmacology*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism*
chemical_list: D024042:Collagen Type I; D011719:Pyrazines; C560822:TIMP1 protein, human; D019715:Tissue Inhibitor of Metalloproteinase-1; C522360:MMP1 protein, human; D020781:Matrix Metalloproteinase 1; D005947:Glucose; C017953:tetramethylpyrazine